Home > News > Clinical Trial of VivaGel for Genital Herpes
June 26th, 2006
Clinical Trial of VivaGel for Genital Herpes
Abstract:
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) today announced the submission of a second Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for a clinical trial of VivaGel™ (SPL7013 Gel). The clinical trial is in support of the product’s second clinical indication, prevention of genital herpes.
Source:
pipelinereview.com
Related Links |
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||